Pevonedistat Granted FDA’s Breakthrough Therapy Status for Higher-Risk MDS: Takeda

Takeda Pharmaceutical said on July 30 that the US FDA has granted breakthrough therapy designation for its investigational drug pevonedistat for the treatment of patients with higher-risk myelodysplastic syndrome (HR-MDS). The drug is currently undergoing a PIII clinical study in...read more